NASDAQ:ALBO
Delisted
Albireo Pharma Inc Stock News
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update
12:30pm, Monday, 02'nd Mar 2020
— Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end — — Management to.
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
07:52pm, Saturday, 29'th Feb 2020
Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved ad
Did Changing Sentiment Drive Albireo Pharma's (NASDAQ:ALBO) Share Price Down By 17%?
02:12pm, Thursday, 27'th Feb 2020
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day 2020 and reaffirms its comm
Albireo to Present at Cowen and Company 40th Annual Health Care Conference
01:30pm, Wednesday, 26'th Feb 2020
BOSTON, Feb. 26, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March 2
01:30pm, Monday, 24'th Feb 2020
BOSTON, Feb. 24, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
NASH: The Second Wave
11:29pm, Thursday, 20'th Feb 2020
Although the first wave (the companies with drugs at Phase-3) is already at the finish line, the effectiveness indicators of these drugs are far from being stro
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten pub
The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
02:26pm, Thursday, 30'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics
